REBEKAH AMIS: Open Payments
NPI 1669065801 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$509 in 19 payments from 8 companies in 2025. Trend: 2023 $291 · 2024 $174 · 2025 $509
Food & beverage: $509
| Company | Payments | Amount |
|---|---|---|
| Organon LLC | 2 | $137 |
| Astellas Pharma US Inc | 5 | $116 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Evofem Biosciences, Inc. | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| MILLICENT US INC | 1 | $28 |
| Biogen, Inc. | 1 | $26 |
Products named: Veozah, MYFEMBREE, Phexxi, INTRAROSA, NEXPLANON, ZURZUVAE, GEMTESA, Mirena.
Industry payments across GA — which companies pay providers there.
